Neferkare IV

Recent publications · Crossref

5 total works indexed

1. Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency

   · 2025 · cited 17x

2. Abstract B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair

   · 2023 · cited 7x

3. Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors

   · 2025 · cited 2x

4. Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

   · 2026 · cited 1x

5. Supplementary Table S14 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency

   · 2025

via Crossref · CC0

Wikidata facts